


Journal of Materials Chemistry B

Materials for biology and medicine

www.rsc.org/MaterialsB



ISSN 2050-750X



PAPER

P. Cigler, L. Brunsveld *et al.*
Carborane- β -cyclodextrin complexes as a supramolecular connector
for bioactive surfaces

PAPER

View Article Online
View Journal | View IssueCite this: *J. Mater. Chem. B*, 2015, 3, 539Carborane- β -cyclodextrin complexes as a supramolecular connector for bioactive surfaces†P. Neiryneck,^a J. Schimer,^b P. Jonkheijm,^c L.-G. Milroy,^a P. Cigler^{*b} and L. Brunsveld^{*a}

Supramolecular chemistry provides an attractive entry to generate dynamic and well-controlled bioactive surfaces. Novel host-guest systems are urgently needed to provide a broader affinity and applicability portfolio. A synthetic strategy to carborane-peptide bioconjugates was therefore developed to provide an entry to monovalent supramolecular functionalization of β -cyclodextrin coated surfaces. The β -cyclodextrin-carborane-cRGD surfaces are formed efficiently and with high affinity as demonstrated by IR-RAS, WCA, and QCM-D, compare favourable to existing bio-active host-guest surface assemblies, and display an efficient bioactivity, as illustrated by a strong functional effect of the supramolecular system on the cell adhesion and spreading properties. Cells seeded on the supramolecular surface displaying bioactive peptide epitopes exhibited a more elongated morphology, focal adhesions, and stronger cell adhesion compared to control surfaces. This highlights the macroscopic functionality of the novel supramolecular immobilization strategy.

Received 9th September 2014
Accepted 28th October 2014

DOI: 10.1039/c4tb01489h

www.rsc.org/MaterialsB

Introduction

Supramolecular host-guest chemistry has recently emerged as a versatile entry for the reversible immobilization of biomolecules on surfaces with retention of activity. For example, functional proteins and peptide epitopes modified with a ferrocene moiety have been immobilized on cucurbit[7]uril (CB7) surfaces with applications in protein arrays.^{1–3} Similarly, beta-cyclodextrin (β CD) monolayers have been widely studied for the immobilization of ferrocene-labeled proteins or peptides *via* the ferrocene- β CD host-guest binding.^{4,5} However, the relatively weak binding of β CD to ferrocene necessitates multivalent interactions to enable efficient surface immobilization on β CD monolayers.^{6,7} Rapid and efficient supramolecular protein and cell adhesion thus requires new guest molecules with alternative chemotypes and strong binding affinities to β CD-functionalized surfaces.

Carboranes are icosahedral cluster compounds consisting of boron, carbon and hydrogen atoms. Their exceptional chemical stability, caused by pseudo-aromatic delocalization of electrons,

as well as their high resistance to biological degradation predisposes carboranes to various biomedical applications. Their high boron content renders carboranes useful for boron neutron capture therapy,⁸ while their well-defined structure and distinctive hydrophobic properties make them useful molecular scaffolds for drug development,^{9,10} including as pharmacophores with tunable geometry and peripheral substitution for the construction of various tight-binding enzyme inhibitors such as carbonic anhydrase¹¹ and HIV protease.¹² Within the supramolecular field carboranes^{13–17} and metallacarboranes^{18–20}




Fig. 1 Bioactive surfaces *via* the supramolecular assembly of carborane- β -cyclodextrin complexes on gold or glass (not shown). A β -cyclodextrin monolayer is supramolecularly coated with a bioactive peptide sequence using the strong monovalent recognition of a carborane conjugated to the cyclic RGD motif. The functionality of the supramolecular platform is evidenced at the macroscopic level *via* the subsequent, substrate selective, recruitment, adhesion, and spreading of cells.

^aLaboratory of Chemical Biology and Institute of Complex Molecular Systems (ICMS), Department of Biomedical Engineering, Eindhoven University of Technology, Den Dolech 2, 5612 AZ, Eindhoven, The Netherlands. E-mail: l.brunsveld@tue.nl; Fax: +31 40 247-8367

^bInstitute of Organic Chemistry and Biochemistry AS CR, v.v.i., Flemingovo nam. 2, Prague 6, 166 10, Czech Republic. E-mail: cigler@uochb.cas.cz; Fax: +420-224-310-090; Tel: +420-220-183-429

^cMolecular Nanofabrication Group, MESA⁺ Institute for Nanotechnology, Department of Science and Technology, University of Twente, P.O. Box 217, 7500 AE, Enschede, The Netherlands. E-mail: p.jonkheijm@utwente.nl

† Electronic supplementary information (ESI) available: LC-MS and NMR analytical data. See DOI: 10.1039/c4tb01489h

are highly appreciated due to their ability to form strong non-covalent complexes with cyclodextrins. For example, the host-guest interaction between β CD and carborane is used for chromatographic separation^{21,22} and for the solubilization of carborane complexes containing platinum(II)-based DNA intercalators.^{23,24}

Here we use 1,2-*closo*-carborane (Cb) as a monovalent supramolecular guest molecule for the efficient non-covalent immobilization of biologically active peptides on β CD surfaces (Fig. 1). We demonstrate the potential utility of the approach for the generation of biomaterials and cell adhesion applications by immobilizing integrin-binding peptides as a means to selectively enhance adhesion and cell spreading of C2C12 cells to the supramolecularly functionalized β CD monolayer.

Materials and methods

TBTU (*O*-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium tetrafluoroborate) was supplied by Iris Biotech. The β CD derivatives were a kind gift from Dr Alejandro Mendez Ardoy (University of Twente, The Netherlands). Amino acids were supplied by Novabiochem. Other chemicals and solvents were purchased from Sigma-Aldrich. Carboranes 1 to 3 were purified using column chromatography on silica (Sigma, pore size 60 Å, 70–230 mesh, 63–200 μ m). The peptide conjugates were purified using a preparative scale RP-HPLC Waters Delta 600 (flow rate 7 mL min⁻¹, gradient shown for each compound – including R_t) with a column Waters SunFire C₁₈ OBD Prep Column, 5 μ m, 19 \times 150 mm. The compound purity was determined by using an analytical Jasco PU-1580 HPLC (flow rate 1 mL min⁻¹, invariable gradient 2–100% MeCN in 30 minutes, R_t shown beside each compound) with a column Watex C₁₈ Analytical Column, 5 μ m, 250 \times 5 mm. Compounds were characterized using HRMS on a LTQ Orbitrap XL (Thermo Fisher Scientific) and NMR (Bruker Avance ITM 400 MHz). Products 4 to 7 were purified using RP-HPLC on a Shimadzu HPLC equipped with a surveyor PDA (C18 preparative column from Phenomenex (21.20 \times 150 mm), flow rate 15 mL min⁻¹). Analysis was performed using a LCQ Fleet from Thermo Scientific on a C18 column equipped with a surveyor AS and PDA. Eluent conditions (CH₃CN/H₂O/0.1% HCO₂H) for 15 min run: 0–1 min, isocratic, 5% CH₃CN; 1–10 min, linear gradient, 5–100%; 10–11 min, isocratic, 100%; 11–12 min, linear gradient, 100–5%; 12–15 min, isocratic, 5% CH₃CN, flow rate 0.1 mL min⁻¹.

Synthesis of carborane-cRGD and carborane-cRAD conjugates

Aminoethyl-*o*-carborane hydrochloride (1). 1.79 g (1.0 eq., 14.7 mmol) of decaborane (KatChem) was dissolved in 50 mL of dry toluene along with 2.75 g (1.0 eq., 14.7 mmol) of 2-(prop-2-yn-1-yl)isindoline-1,3-dione. 1.286 g (0.5 eq., 7.36 mmol) of 1-butyl-3-methylimidazolium chloride was added and the reaction mixture was refluxed overnight. The toluene was then evaporated and the organic slurry was extracted thrice with Et₂O (50 mL). Organic phases were combined and evaporated to dryness. The product was further recrystallized from hot DCM

to obtain the pure product at 41% yield (1.821 g, 8.72 mmol). The next two steps in synthesis were conducted as described previously and the data collected were identical to previously reported data.²⁵

Carborane-cysteine (3). 530 mg (1.2 eq., 1.14 mmol) of Boc-Cys(Trt)-OH was weighed out in a round-bottom flask and dissolved in 3 mL of DMF. TBTU (367 mg, 1.2 eq., 1.14 mmol) and DIPEA (367 μ L, 3.5 eq., 3.34 mmol) were then added and the reaction mixture was left stirring for 15 min after which (aminoethyl)-*o*-carborane hydrochloride 1 (200 mg, 1.0 eq., 0.95 mmol) was added in one portion. All volatiles were evaporated after 12 h and the organic slurry was dissolved in 20 mL of EtOAc. This solution was then washed twice with a 10% solution of KHSO₄ (20 mL), twice with a saturated solution of NaHCO₃ (20 mL) and once with brine. The organic layer was then dried and evaporated. The crude product was purified by column chromatography (hexane:EtOAc 5 : 1, R_f = 0.35; UV detection). 350 mg (0.57 mmol) of the protected product 2 was obtained in a 65% yield. The trityl- and boc- protecting groups were then cleaved off by treating 2 for 1 h with 1 mL of TFA/H₂O/triisopropylsilane (95/2.5/2.5, % v/v). Purification by preparative scale HPLC (gradient 15–50% MeCN in 40 minutes; R_t = 17 min) afforded 65 mg of 3 as a white powder upon lyophilization (42% yield, purity >95%). Note that the addition of acetone to 3 leads to stable thiazolid-2-one. Analytical HPLC R_t = 18.5 min. HRMS (ESI+): calculated for C₆H₂₁ON₂SB₁₀ [MH]⁺ 279.22997. Found 279.23010. ¹H NMR (400 MHz, CD₃CN) δ 8.11 (bs, 1H), 4.33 (bs, 1H), 4.22 (t, J = 5.4 Hz, 2H), 3.98 (qd, J = 15.3, 6.7 Hz, 2H), 3.06 (ddd, J = 20.7, 14.9, 5.3 Hz, 2H), 2.85–1.35 (m, 12H). ¹³C NMR (101 MHz, CD₃CN) δ 168.46 (s), 75.86 (s), 62.02 (s), 55.52 (s), 45.03 (s), 26.07 (s). ¹¹B NMR (128 MHz, CD₃CN, decoupled) δ –2.99 (s), –5.88 (s), –9.99 (s), –11.86 (s), –13.20 (s).

cRGD-maleimide (4) and cRAD-maleimide (5). cRGD and cRAD were synthesized according to previous literature.² 20 mg of the peptide was reacted with NHS-activated maleimide (synthesized according to previous literature, see ESI†)²⁶ (1.4 eq.) in dry DMF (1 mL) for 1 h at rt in the presence of DIPEA (4 eq.). The solvents were then removed *in vacuo* and the peptide-maleimide conjugates were purified by preparative-RP HPLC (gradient 10–25% MeCN, 0.1% HCO₂H in 20 min) to afford cRGD-maleimide 4 and cRAD-maleimide 5 in yields of 25% and 28%, respectively, both as white powders. 4: Analytical HPLC R_t = 2.55 min. MS (ESI+): calculated for C₃₄H₄₆N₁₀O₁₀ [MH]⁺ 755.79 Found 755.67. 5: Analytical HPLC R_t = 2.55 min. MS (ESI+): calculated for C₃₅H₄₉N₁₀O₁₀ [MH]⁺ 769.79 found 769.67.

Cb-cRGD (6) and Cb-cRAD (7). 5.8 mg of cRGD-maleimide (resp. 3 mg of cRAD-maleimide) was dissolved in PBS (30 mM sodium phosphate, 50 mM NaCl, pH 7.4) and added to 1 (1 eq.) dissolved in 1 mL DMF. The reaction was stirred at room temperature for 1 h and the solvents were removed *in vacuo*. Purification was performed using preparative RP-HPLC (gradient 20–50% MeCN, 0.1% HCO₂H in 30 min). Yields for Cb-cRGD 6 and Cb-cRAD 7 were 63 and 5%, respectively. 6: Analytical HPLC R_t = 4.48 min. MS (ESI+): calculated for C₄₀H₆₇B₁₀N₁₂O₁₁S [MH]⁺ 1033.21. Found 1032.75. 7: Analytical



HPLC R_t = 4.49 min. MS (ESI⁺): calculated for $C_{41}H_{70}B_{10}N_{12}O_{11}S$ $[MH]^+$ 1047.25. Found 1046.75.

Surface chemistry

β CD immobilization on glass coverslips. Glass coverslips were sonicated for 10 min in Hellmanex, then twice for 5 min in H_2O , dried under N_2 flow and exposed to O_2 plasma for 30 s. The surfaces were thoroughly washed with H_2O , then with EtOH and dried under N_2 flow. The surfaces were placed in a vacuum desiccator overnight with (trimethoxysilyl) propyl-ethylenediamine (TPEDA). The next day, the surfaces were washed with EtOH, dipped in dry toluene and then dried. Then they were incubated in a 1 mM toluene solution of 1,4-phenylene diisothiocyanate at 50 °C for 2 h under a N_2 atmosphere, washed with toluene, EtOH and water, and subsequently incubated for 2 h at 50 °C with a 1 mM solution of per-6-amino- β -cyclodextrin (β CD-7NH₂, **8**, Scheme 1) in H_2O .²⁷ Finally, the surfaces were washed sequentially with H_2O , EtOH and then thoroughly dried under N_2 flow.

Where applicable, substrates were then incubated for 3 h with 75 μ L of a 100 μ M aqueous solution of the carborane-peptide conjugate, rinsed with H_2O and dried under N_2 flow.

β CD immobilization on gold substrates. Prior to use in QCM-D experiments, resonators were activated for 15 s using a piranha solution (H_2SO_4/H_2O_2 , 3 : 1, % v/v). Surfaces were then extensively washed with H_2O and EtOH, and then incubated in a 1 mM solution of heptakis[6-deoxy-6-[12-(thiododecyl)

undecanamido]]- β -cyclodextrin (β CD-7S, **9**, Scheme 1) for efficient immobilization^{28,29} in $CHCl_3$ /EtOH 2/1, heated at 60 °C for 1 h, and then left at room temperature overnight, under a N_2 atmosphere. They were then rinsed with EtOH and dried under N_2 flow. The same protocol was followed for the preparation of substrates for IR-RAS analysis. Where applicable, the substrates were then incubated for 3 h with 75 μ L of a 100 μ M aqueous solution of the carborane-peptide conjugate, rinsed with H_2O and dried under N_2 flow.

Characterization of β CD-carborane-peptide surfaces. Fourier Transform Infrared Reflection Absorption Spectroscopy (FT-IR-RAS) measurements utilized 200 nm gold Si wafers, 2 × 2 cm. The polarized FT-IR-RAS spectra of 1000 scans with a resolution of 2 cm^{-1} were obtained using a Thermo Scientific TOM optical module.

Water contact angle measurements were performed on a Krüss G10 contact angle measuring instrument, equipped with a CCD camera. Images were analyzed using the Drop Shape Analysis software version 1.90.0.2 and the ImageJ Contact Angle plugin.


QCM-D studies. QCM-D data were measured using a Q-Sense E1 with a peristaltic pump, Ismatec Reglo Digital M2-2/12. Gold-coated QCM-D resonators QSX 301 with a resonance frequency of 4.95 MHz \pm 0.05 MHz were purchased from LOT-Quantum-Design. All solutions of Cb-cRGD were prepared using PBS buffer. Measurements were performed at 20 °C, with a flow of 50 μ L min^{-1} . Prior to the binding of the Cb-RGD **6**, surfaces were equilibrated by flowing over PBS buffer until a stable baseline was obtained.

Cell culture and adhesion studies

C2C12 cells, from a mouse myoblast cell line, were used at passage between 15 and 20 for the cell experiments. 80% confluent T25 or T75 flasks of C2C12 were trypsinized, centrifuged and redispersed in DMEM medium supplemented with penicillin/strep, NEAA, as well as 10% FBS for culturing and 0% FBS for surface incubation experiments.

Glass substrates coated with β CD and carborane-peptide were dipped in and out into 70% EtOH and rinsed twice with PBS. Cells in suspension in 0% FBS supplemented DMEM media were seeded on the substrates (20 000 cells per mL, 3 mL per well) and left to adhere for 1 h at 37 °C and 5% CO_2 . The surfaces were then gently washed twice with PBS and cells were fixed for 10 min with 10% formalin and then rinsed three times with PBS.

Cells were incubated with blocking solution (0.1% Triton, 0.5% w/w BSA in PBS pH 7.4) for 1 h at room temperature or overnight at 4 °C. The surfaces were then incubated with Paxillin **1** : 500 in blocking buffer for 1 h, washed 3 times for 10 min with blocking buffer, and incubated for 1 h with the secondary antibody-Alexa 488 (**1** : 500) and phalloidin-Alexa 546 (**1** : 500) in blocking buffer. Finally the surfaces were washed once for 10 min with blocking buffer and twice with PBS, incubated for 10 min with DAPI in PBS (**1** : 1000), rinsed with PBS three times, and then stored at 4 °C.



Scheme 1 Structures of β CD-7NH₂ **8** (ref. 27) and β CD-7S **9** (ref. 28 and 29) and synthesis of carborane-thiol **3** and peptide-carborane conjugates, **6** (cRGD) and **7** (cRAD). (a) 2-(Prop-2-yn-1-yl)isoindoline-1,3-dione, [BMIM]Cl, toluene, 110 °C; (b) NaBH₄, *i*-PrOH/ H_2O ; (c) AcOH/ H_2O , HCl, 75 °C; (d) Boc-Cys(Trt)-OH, TBTU, DIPEA, DMF; (e) TFA/ H_2O /TIS; (f) DMF/PBS 1/1% (v/v), 1 h, rt. BMIM = 1-butyl-3-methylimidazolium, TBTU = *O*-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium tetrafluoroborate, DIPEA = *N,N*-diisopropylethylamine, DMF = *N,N*-dimethylformamide, TIS = triisopropylsilane.



Imaging was performed using an Olympus IX71 fluorescence microscope, at 40 \times magnification. Five pictures per substrate were recorded for each of the three repetitions and analysis of the cell adhesion was performed using CellProfiler.³⁰ Cells that could not be recognized by the software or that did not fall completely in the field of view were discarded from the analysis. On average, between 30 and 40 cells per substrate per set remained for analysis, corresponding to approximately 100 cells per condition. Results were normalized towards the average value obtained for each experiment set for the β CD control surface. All experiments were performed in triplicate.

Results and discussion

Synthesis

Our aim was to develop conditions to couple the carborane to biomolecules, which might be compatible with a broad range of molecules including peptides and proteins. Therefore thiol-functionalized carboranes^{31–34} were explored to react with maleimide modified peptides under mild conditions. Direct connection of the thiol to the Cb cage^{31,32} is expected to lead to steric hindrance regarding β CD binding and peptide conjugation. A water-soluble Cb bearing a thiol group attached *via* a short linker,^{33,34} would constitute a more beneficial starting point. Therefore, the 1-aminomethyl-1,2-*closo*-carborane precursor was first prepared in three steps starting from decaborane B₁₀H₁₄ (see Scheme 1). We modified the previously published synthesis²⁵ procedure by implementing a recently described acetylene insertion methodology, which is performed in an ionic liquid.³⁵ The aminomethyl-carborane **1** was then coupled to the protected cysteine Boc-Cys(Trt)-OH *via* TBTU activation and the desired product, **3**, was obtained upon treatment with TFA/H₂O/triisopropylsilane (95/2.5/2.5, % v/v) without evidence of thiol capping. Peptide activation was performed at pH 7 to favor selective coupling of the NHS-activated maleimide to the lysine, providing **4** and **5**. Reactions between the Cys-functionalized Cb and the maleimide-cRGD and maleimide-cRAD were performed in a 1 : 1 (v/v) mixture of DMF/PBS at pH 7–7.5 to afford the target compounds **6** and **7**.

Surface characterization

Water contact angle (WCA) measurements were performed to provide information on changes in the hydrophilicity of the surface upon successive monolayer formation (Fig. 2). A large decrease in the contact angle was observed – from 95 to 49° – after functionalization of the gold surface with β CD-7S, which



Fig. 2 Water contact angle values for gold, β CD monolayer and β CD complexed with Cb-cRGD **6** ($n = 4$), with a representative picture. A high WCA angle value indicates a hydrophobic surface.

displays several OH groups and thus increases the hydrophilicity of the surface. Subsequent incubation with Cb-cRGD, **6**, resulted in a small increase in the WCA of the polar surface from 49 to 56°, in agreement with previously reported values for RGD functionalized surfaces.²

To get more insight into the formation of the β CD·Cb complex on gold, substrates functionalized with β CD-7S^{28,29} and further incubated with Cb-cRGD **6** were studied by Infrared Reflection Absorption Spectroscopy (IR-RAS). The IR spectrum of β CD³⁶ in solution exhibits characteristic absorption peaks at 1053, 1088, 1157, 1204, 1241 and 1267 cm^{−1} – corresponding to different stretching (CO and CC), and bending modes (COH, OCH and CCH), which are also observed on the gold surface (Fig. 3). Sharp peaks at 1654 cm^{−1} (β CD) and 1661 cm^{−1} (β CD + Cb-cRGD) were observed corresponding to the C=O stretch of amides present in the β CD-7S structure as well as in the cRGD peptide conjugates, while the intense broad peak at 3345 cm^{−1} is characteristic of the presence of secondary OH groups. A peak at 2582 cm^{−1} (B–H) (Fig. 3 top, arrow) is observed in the case of β CD + Cb-cRGD, which is indicative of complexation between β CD and Cb and has also been observed for a similar system in solution.^{37,38} Both surface analyses provide convincing evidence for the immobilization of carborane-peptide conjugates to the β CD-7S gold monolayers *via* the β CD·carborane complexation.

Host-guest surface complexation

Quartz Crystal Microbalance with Dissipation monitoring (QCM-D) measurements were performed for a more detailed




Fig. 3 FT-IR-RAS of β CD (red) and β CD + Cb-cRGD, **6** (black) on gold, in two different regions (top: 3600–2000 cm^{−1}, bottom: 2000–1000 cm^{−1}). The arrow shows a characteristic peak of the β CD·carborane complex.



and quantitative analysis of the affinity of Cb-cRGD (**6**) for β CD monolayers. In general, a change at the surface of a quartz crystal sensor, for example *via* binding of a compound, results in a measurable change in the vibration frequency of the sensor. Various concentrations of Cb-cRGD (**6**) in PBS, ranging from 10 to 500 μ M, were flown over gold crystals pre-functionalized with β CD-7S (Fig. 4a). Dissipation remained within 10% of the change in the frequency value, indicating the formation of a rigid film at the resonator surface and allows the Sauerbrey model to be applied.³⁹ The change in frequency of the 5th resonance was plotted *versus* the concentration of **6** (Fig. 4b) and the resulting graph could be fitted with a Langmuir model, providing a K_d value of $178 \mu\text{M} \pm 39 \mu\text{M}$ for the interaction of **6** with the β CD monolayer, *via* the Cb mediated host-guest interaction.

The affinity of carborane **6** for the β CD monolayer can be compared favorably with other known guests of β CD, such as ferrocene and adamantane. Carborane binds to β CD with 5-fold greater affinity than aminomethylferrocene derivatives and is therefore better suited for monovalent surface immobilization.⁴ Lithocholic acid binds to β CD with high binding affinity in solution ($K_d = 1.2 \times 10^{-6}$ M), but has limited potential for β CD surface interactions due to the guest protruding the β CD at the smaller ring, resulting in lowered affinities.⁴⁰ The affinities of carborane and adamantane for a β CD monolayer are comparable.⁴¹ However, carborane introduces to the system a unique quality: high content of boron, which in principle can be further

utilized for quantification of conjugation yields using a sensitive spectral method such as inductively atomic emission spectrometry with inductively coupled plasma (ICP-AES), as has been shown for boron-containing BODIPY dyes.⁴²

Cellular evaluation of the surfaces

Strong and directional supramolecular surface immobilization strategies provide substantial opportunities for biomedical applications. To explore the potential of the β CD-Cb complex in this respect, the ability of surface-immobilized Cb-cRGD conjugates to induce specific cell adhesion was studied using the C2C12 mouse myoblast cell line. C2C12 cells express various integrin receptors, including $\alpha_v\beta_3$, which is known to bind to cRGDfK, as used in **6**,^{43,44} and show clear phenotypic changes to the environment.^{45,46} For these experiments, cells were passaged at 80% confluence to avoid differentiation. While the surface characterization was performed on gold surfaces coated with β CD (*vide supra*), glass surfaces are more suitable for fluorescence microscopy studies and were thus favored for the cell experiments. Surfaces featuring a β CD monolayer and a β CD monolayer complexed with the bio-inactive conjugate Cb-cRAD 7 were used as reference surfaces. Cyclodextrins are composed of oligomerized glucose and therefore do not specifically discourage cell adhesion, but lack a specific molecular entity to enhance cell spreading, such as the bioactive epitope cRGD. Cells seeded on either the control β CD or β CD + Cb-cRAD substrates remained round and did not form proper focal adhesions (Fig. 5a and b). However, cells seeded on the β CD + Cb-cRGD surfaces became strongly anchored to the surface, evident already within 1 h of seeding, with pronounced stretching of actin filaments as a consequence of cell and focal adhesion (Fig. 5c). These results show that the cells specifically recognize the RGD sequence through binding to integrins, and that the differences in the cell morphology observed between the β CD + Cb-cRGD and β CD + Cb-cRAD surfaces are a specific consequence of the difference in integrin binding affinities between the supramolecular immobilized cRGD and cRAD.⁴⁷

A more in-depth analysis of the cell adhesion was performed using CellProfiler³⁰ to obtain a quantitative difference in cellular morphological properties under the different surface immobilization conditions (Fig. 6). Similar studies have been performed to correlate qualitative and quantitative aspects of cell pictures.^{48,49} A workflow chart providing information about *e.g.* cell area, perimeter or eccentricity was run and data were




Fig. 4 QCM-D data for binding of Cb-cRGD (**6**) to β CD-7S coated quartz crystals. (a) Fifth resonance frequency overtone (Δf_5) for various concentrations of Cb-cRGD (10, 50, 100, 250, and 500 μ M). (b) Change in frequency of the fifth overtone *versus* Cb-cRGD concentration. The fit was performed using Origin, Langmuir fit, resulting in a K_d value of $178 \mu\text{M} \pm 39 \mu\text{M}$.




Fig. 5 Scale bar: 50 μ m. C2C12 seeded on glass surfaces coated with (a) β CD, (b) β CD and Cb-cRAD, and (c) β CD and Cb-cRGD, fixed after 1 h and stained for the nucleus (DAPI) and actin (Phalloidin). The focal adhesions are exemplarily indicated by the white arrows.






Fig. 6 Statistical analysis of the cell experiments with CellProfiler³⁰ and GraphPad Prism. Data were normalized and averaged for each repetition towards the control β CD.

analyzed using the software GraphPad Prism. A repeated-measures one-way analysis of variance (one-way ANOVA) test was applied on the normalized averages for each repetition and each condition. As already indicated by the simple visual aspect and observation of the focal adhesions, statistically noticeable differences in the eccentricity, perimeter, form factor, compactness and ratio between the major and minor axis lengths was only observed for the β CD monolayer complexed with Cb-cRGD compared to β CD; there is a significant difference ($p < 0.05$) between the control surface β CD and the active surface (β CD with Cb-cRGD).

Some of the morphological characteristic changes strongly correlate with one another. For example, the eccentricity describes the elliptical character of the cell morphology (Fig. 6a): an increase in eccentricity describes a shape that transitions from a circle, through an ellipse, to a line. In line with this, the ratio of the major axis length divided by the minor axis length will be higher in the case of an elongated cell compared to a cell displaying a more rounded morphology (Fig. 6b). These observations can specifically be made for the supramolecular adhered cells; the eccentricity increases from 1 for β CD to 1.12 for the Cb-cRGD surface. The ratio of the axis lengths also increases, from 1 to 1.14. The form factor is defined as $4\pi \cdot \text{area} / \text{perimeter}^2$: this value will be equal to 1 for a circle and will decrease as the perimeter of the cell increases (Fig. 6c). An increase in the perimeter (from 1 to 1.24) (Fig. 6d) can be observed which correlates with a decrease in the form factor (1 to 0.76). These results confirm the qualitative observation from the pictures and thus the functional effect of the supramolecular system on the cell adhesion and spreading properties: cells are more elongated and functionally adhered on the β CD + Cb-cRGD surface than on the control surfaces.

Conclusions

Supramolecular systems offer great opportunities for the development of dynamic and well-controlled biocompatible surfaces and coatings. Existing host-guest elements require optimization regarding affinity and applicability. Here, we reported the synthesis of a carborane derivative mono-functionalized with cysteine for conjugation to biologically relevant molecules, such as peptides, under mild conditions. The utility of the approach was demonstrated by conjugating the cysteine-carborane derivative to cRGD analogs *via* Michael 1,4-addition to a maleimide group under ambient conditions (room temperature, pH 7–7.5). Though not demonstrated here, the functionalization of whole proteins with the cysteine-carborane derivative *via* expressed protein ligation or maleimide coupling should also be possible. Formation of the β CD-carborane-cRGD complex on surfaces was demonstrated by IR-RAS and WCA, and the binding affinity was quantified by QCM-D, comparing favorable to existing bio-active host-guest assemblies on β CD surfaces. Cells seeded on β CD + Cb-cRGD substrates exhibited a more elongated morphology and stronger cell adhesion compared to control β CD and β CD + Cb-cRAD substrates, showing the functionality of the supramolecular immobilization strategy on the macroscopic level. This opens new possibilities to generate innovative and robust supramolecular surfaces of biomedical interest.

Acknowledgements

This research forms part of the Project P4.02 Superdices of the research program of the BioMedical Materials Institute, co-funded by the Dutch Ministry of Economic Affairs, Agriculture and Innovation and the Netherlands Organisation for Scientific Research *via* the Gravity program 024.001.035 and ERC grant 259183 – Sumoman (PJ). The work of PC and JS was supported by MSMT CR grant no. LH11027. Dr Alejandro Mendez Arday is thanked for the synthesis of the β CD derivatives.

Notes and references

- 1 J. F. Young, H. D. Nguyen, L. Yang, J. Huskens, P. Jonkhøj and L. Brunsveld, *ChemBioChem*, 2010, **11**, 180–183.
- 2 P. Neiryck, J. Brinkmann, Q. An, D. W. J. van der Schaft, L.-G. Milroy, P. Jonkhøj and L. Brunsveld, *Chem. Commun.*, 2013, **49**, 3679–3681.
- 3 I. Hwang, K. Baek, M. Jung, Y. Kim, K. M. Park, D.-W. Lee, N. Selvapalam and K. Kim, *J. Am. Chem. Soc.*, 2007, **129**, 4170–4171.
- 4 L. Yang, A. Gomez-Casado, J. F. Young, H. D. Nguyen, J. Cabanas-Danés, J. Huskens, L. Brunsveld and P. Jonkhøj, *J. Am. Chem. Soc.*, 2012, **134**, 19199–19206.
- 5 D. Thakar, L. Coche-Guérente, M. Claron, C. H. F. Wenk, J. Dejeu, P. Dumy, P. Labbé and D. Boturyn, *ChemBioChem*, 2014, **15**, 377–381.
- 6 J. Guo, C. Yuan, M. Guo, L. Wang and F. Yan, *Chem. Sci.*, 2014, **5**, 3261–3266.



- 7 M. Ortiz, M. Torr  ns, A. Fragoso and C. K. O'Sullivan, *Anal. Bioanal. Chem.*, 2012, **403**, 195–202.
- 8 R. F. Barth, J. A. Coderre, M. G. H. Vicente and T. E. Blue, *Clin. Cancer Res.*, 2005, **11**, 3987–4002.
- 9 F. Issa, M. Kassiou and L. M. Rendina, *Chem. Rev.*, 2011, **111**, 5701–5722.
- 10 M. Scholz and E. Hey-Hawkins, *Chem. Rev.*, 2011, **111**, 7035–7062.
- 11 J. Brynda, P. Mader, V.   icha, M. F  bry, K. Poncov  , M. Bakardiev, B. Gr  ner, P. C  gler and P. Rezacov  , *Angew. Chem.*, 2013, **125**, 14005–14008.
- 12 P. C  gler, M. Ko  i  ek, P. Rezacov  , J. Brynda, Z. Otwinowski, J. Pokorn  , J. Ple  ek, B. Gr  ner, L. Dole  kov  -Mare  ov  , M. M   a, J. Sedl   ek, J. Bodem, H.-G. Kr  usslich, V. Kr  l and J. Konvalinka, *Proc. Natl. Acad. Sci. U. S. A.*, 2005, **102**, 15394–15399.
- 13 A. Harada and S. Takahashi, *Chem. Commun.*, 1988, 1352–1353.
- 14 C. Frixa, M. Scobie, S. J. Black, A. S. Thompson and M. D. Threadgill, *Chem. Commun.*, 2002, 2876–2877.
- 15 K. Ohta, S. Konno and Y. Endo, *Tetrahedron Lett.*, 2008, **49**, 6525–6528.
- 16 R. Vaitkus and S. S  j  berg, *J. Inclusion Phenom. Macrocyclic Chem.*, 2011, **69**, 393–395.
- 17 H. Y. V. Ching, S. Clifford, M. Bhadbhade, R. J. Clarke and L. M. Rendina, *Chem.–Eur. J.*, 2012, **18**, 14413–14425.
- 18 P. A. Chetcuti, P. Moser and G. Rihs, *Organometallics*, 1991, **10**, 2895–2897.
- 19 J. Rak, M. Jakubek, R. Kapl  nek, P. Mat  j   ek and V. Kr  l, *Eur. J. Med. Chem.*, 2011, **46**, 1140–1146.
- 20 M. Uchman, P. Jurkiewicz, P. C  gler, B. Gr  ner, M. Hof, K. Procha  zka and P. Mat  j   ek, *Langmuir*, 2010, **26**, 6268–6275.
- 21 H. Hor  kov  , B. Gr  ner and R. Vespalec, *Chirality*, 2011, **23**, 307–319.
- 22 P. Mat  j   ek, M. Uchman, M. Lep     k, M. Srnec, J. Zedn   k, P. Kozl  k and K. Kal  kov  , *ChemPlusChem*, 2013, **78**, 528–535.
- 23 H. Y. V. Ching, D. P. Buck, M. Bhadbhade, J. G. Collins and L. M. Rendina, *Chem. Commun.*, 2012, **48**, 880.
- 24 H. Y. V. Ching, R. J. Clarke and L. M. Rendina, *Inorg. Chem.*, 2013, **52**, 10356–10367.
- 25 J. G. Wilson, A. K. M. Anisuzzaman, F. Alam and A. H. Soloway, *Inorg. Chem.*, 1992, **31**, 1955–1958.
- 26 H. Y. Song, M. H. Ng  i, Z. Y. Song, P. A. MacAry, J. Hobley and M. J. Lear, *Org. Biomol. Chem.*, 2009, **7**, 3400–3406.
- 27 P. R. Ashton, R. K  niger, J. F. Stoddart, D. Alker and V. D. Harding, *J. Org. Chem.*, 1996, **61**, 903–908.
- 28 M. W. J. Beulen, J. B  gler, M. R. de Jong, B. Lammerink, J. Huskens, H. Sch  nherr, G. J. Vancso, B. A. Boukamp, H. Wieder, A. Offenh  user, W. Knoll, F. C. J. M. van Veggel and D. N. Reinhoudt, *Chem.–Eur. J.*, 2000, **6**, 1176–1183.
- 29 M. W. J. Beulen, J. B  gler, B. Lammerink, F. A. J. Geurts, E. M. E. F. Biemond, K. G. C. van Leerdam, F. C. J. M. van Veggel, J. F. J. Engbersen and D. N. Reinhoudt, *Langmuir*, 1998, **14**, 6424–6429.
- 30 A. E. Carpenter, T. R. Jones, M. R. Lamprecht, C. Clarke, I. H. Kang, O. Friman, D. A. Guertin, J. H. Chang, R. A. Lindquist, J. Moffat, P. Golland and D. M. Sabatini, *Genome Biol.*, 2006, **7**, R100.
- 31 J. Ple  ek and S. He  m  nek, *Collect. Czech. Chem. Commun.*, 1981, **46**, 687–692.
- 32 L. I. Zakharkin and G. G. Zhigareva, *Russ. Chem. Bull.*, 1967, **16**, 1308–1310.
- 33 J. A. Todd, P. Turner, E. J. Ziolkowski and L. M. Rendina, *Inorg. Chem.*, 2005, **44**, 6401–6408.
- 34 D. Pietrangeli, A. Rosa, A. Pepe and G. Ricciardi, *Inorg. Chem.*, 2011, **50**, 4680–4682.
- 35 Y. Li, P. J. Carroll and L. G. Sneddon, *Inorg. Chem.*, 2008, **47**, 9193–9202.
- 36 O. Eged, *Vib. Spectrosc.*, 1990, **1**, 225–227.
- 37 A. Harada and S. Takahashi, *Chem. Commun.*, 1988, 1352–1353.
- 38 T. J. Tague and L. Andrews, *J. Am. Chem. Soc.*, 1994, **116**, 4970–4976.
- 39 G. Sauerbrey, *Z. Physik*, 1959, **155**, 206–222.
- 40 Z. Yang and R. Breslow, *Tetrahedron Lett.*, 1997, **38**, 6171–6172.
- 41 D. A. Uhlenheuer, D. Wasserberg, C. Haase, H. D. Nguyen, J. H. Schenkel, J. Huskens, B. J. Ravoo, P. Jonkheijm and L. Brunsveld, *Chem.–Eur. J.*, 2012, **18**, 6788–6794.
- 42 P. C  gler, A. K. R. Lytton-Jean, D. G. Anderson, M. G. Finn and S. Y. Park, *Nat. Mater.*, 2010, **9**, 918–922.
- 43 U. Hersel, C. Dahmen and H. Kessler, *Biomaterials*, 2003, **24**, 4385–4415.
- 44 K.-E. Gottschalk and H. Kessler, *Angew. Chem., Int. Ed.*, 2002, **41**, 3767–3774.
- 45 S. Weis, T. T. Lee, A. del Campo and A. J. Garc  a, *Acta Biomater.*, 2013, **9**, 8059–8066.
- 46 P.-Y. Wang, T.-H. Wu, W.-B. Tsai, W.-H. Kuo and M.-J. Wang, *Colloids Surf., B*, 2013, **110**, 88–95.
- 47 G. J. Strijkers, E. Kluza, G. A. F. V. Tilborg, D. W. J. van der Schaft, A. W. Griffioen, W. J. M. Mulder and K. Nicolay, *Angiogenesis*, 2010, **13**, 161–173.
- 48 J. Boekhoven, C. M. Rubert P  rez, S. Sur, A. Worthy and S. I. Stupp, *Angew. Chem., Int. Ed.*, 2013, **52**, 12077–12080.
- 49 J. E. Gautrot, J. Malmstr  m, M. Sundh, C. Margadant, A. Sonnenberg and D. S. Sutherland, *Nano Lett.*, 2014, **14**, 3945–3952.

